Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Axsome Therapeutics, Inc., Amylyx Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Latest Pharmaceuticals and Axsome Therapeutics, Inc., Amylyx Pharmaceuticals, Inc. Stock News

As of October 9, 2026, Axsome Therapeutics, Inc. had a $8.8 billion market capitalization, compared to the Pharmaceuticals median of $519.2 million. Axsome Therapeutics, Inc.’s stock is down 7.8% in 2026, down 6.1% in the previous five trading days and up 41.82% in the past year.

Currently, Axsome Therapeutics, Inc. does not have a price-earnings ratio. Axsome Therapeutics, Inc.’s trailing 12-month revenue is $776.6 million with a -24.7% net profit margin. Year-over-year quarterly sales growth most recently was 45.6%. Analysts expect adjusted earnings to reach $-2.766 per share for the current fiscal year. Axsome Therapeutics, Inc. does not currently pay a dividend.

As of October 9, 2026, Amylyx Pharmaceuticals, Inc. had a $3.5 billion market cap, putting it in the 63rd percentile of all stocks. Amylyx Pharmaceuticals, Inc.’s stock is up 132.9% in 2026, up 1.3% in the previous five trading days and up 108.75% in the past year.

Currently, Amylyx Pharmaceuticals, Inc. does not have a price-earnings ratio. Amylyx Pharmaceuticals, Inc.’s trailing 12-month revenue is $0.0 million with a % net profit margin. As of October 9, 2026, Amylyx Pharmaceuticals, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-1.497 per share for the current fiscal year. Amylyx Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
Axsome Therapeutics, Inc.	AXSM	F
Amylyx Pharmaceuticals, Inc.	AMLX	na

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Axsome Therapeutics, Inc. has a Value Score of 4, which is Ultra Expensive. Amylyx Pharmaceuticals, Inc. does not have a meaningful Value Score.

The Value Stock Winner: No Clear Winner

Neither Axsome Therapeutics, Inc., Amylyx Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Axsome Therapeutics, Inc., Amylyx Pharmaceuticals or Inc. is the better investment when it comes to value.

Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Axsome Therapeutics, Inc.	AXSM	C
Amylyx Pharmaceuticals, Inc.	AMLX	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Axsome Therapeutics, Inc. has a Quality Score of 42, which is Average. Amylyx Pharmaceuticals, Inc. has a Quality Score of 19, which is Very Weak.

The Quality Stock Winner: No Clear Winner

Neither Axsome Therapeutics, Inc., Amylyx Pharmaceuticals or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Axsome Therapeutics, Inc., Amylyx Pharmaceuticals or Inc. is the better investment when it comes to quality.

Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Axsome Therapeutics, Inc.	AXSM	C
Amylyx Pharmaceuticals, Inc.	AMLX	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Axsome Therapeutics, Inc. has a Momentum Score of 60, which is Average. Amylyx Pharmaceuticals, Inc. has a Momentum Score of 95, which is Very Strong.

The Momentum Grade Winner: Amylyx Pharmaceuticals, Inc.

As you can clearly see from the Momentum Grade breakdown above, Amylyx Pharmaceuticals, Inc. is considered to have stronger momentum compared to Axsome Therapeutics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Amylyx Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc. Grades

In addition to Quality, Value and Momentum, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Axsome Therapeutics, Inc., Amylyx Pharmaceuticals or Inc. Stock?

Overall, Axsome Therapeutics, Inc. stock has a Value Score of 4, Momentum Score of 60 and Quality Score of 42.

Amylyx Pharmaceuticals, Inc. stock has a Value Score of , Momentum Score of 95 and Quality Score of 19.

Comparing Axsome Therapeutics, Inc., Amylyx Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.